Enzo Biochem Stock Return On Equity

ENZ Stock

USD 1.08 0.05 4.85%

Enzo Biochem fundamentals help investors to digest information that contributes to Enzo Biochem's financial success or failures. It also enables traders to predict the movement of Enzo Stock. The fundamental analysis module provides a way to measure Enzo Biochem's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enzo Biochem stock.

		Last Reported	Projected for Next Year
	Return On Equity	(0.46)	(0.49)

Return On Equity is likely to drop to -0.49 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Enzo Biochem Company Return On Equity Analysis

Enzo Biochem's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Enzo Biochem Return On Equity

-0.15

Most of Enzo Biochem's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Enzo Biochem is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Enzo Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Enzo Biochem is extremely important. It helps to project a fair market value of Enzo Stock properly, considering its historical fundamentals such as Return On Equity. Since Enzo Biochem's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enzo Biochem's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enzo Biochem's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Accounts Payable	Short Term Debt	Common Stock	Good Will	Property Plant Equipment	Short Term Investments	Current Deferred Revenue	Long Term Debt	Net Tangible Assets	Capital Surpluse	Short Long Term Debt	Long Term Debt Total	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.83	-0.54	-0.15	-0.18	0.23	0.9	-0.59	0.01	0.1	0.47	0.0	0.47	0.14	-0.44	0.37	0.79	0.41	-0.35	0.42	-0.3	-0.28	-0.44	0.24
Total Stockholder Equity	0.83		-0.77	-0.33	0.17	-0.34	0.87	-0.38	0.25	-0.2	0.58	-0.09	0.24	-0.14	-0.4	0.09	0.84	0.37	-0.58	0.16	-0.1	-0.08	-0.12	0.18
Net Debt	-0.54	-0.77		0.14	-0.05	0.44	-0.8	0.1	-0.02	0.49	-0.37	0.12	0.2	0.49	0.24	0.41	-0.78	-0.39	0.4	0.35	-0.5	-0.07	-0.19	-0.25
Retained Earnings	-0.15	-0.33	0.14		-0.38	0.33	-0.01	-0.33	-0.34	-0.27	-0.9	0.49	-0.41	0.38	-0.39	-0.22	-0.2	-0.42	0.16	-0.16	0.19	0.35	0.35	-0.28
Net Receivables	-0.18	0.17	-0.05	-0.38		-0.54	-0.12	0.07	0.92	0.15	0.28	-0.31	-0.21	-0.21	0.15	-0.12	-0.16	-0.42	0.12	-0.08	0.17	0.6	0.55	-0.61
Total Liab	0.23	-0.34	0.44	0.33	-0.54		0.01	-0.35	-0.36	0.53	-0.2	0.05	0.39	0.49	-0.03	0.49	-0.12	0.01	0.43	0.45	-0.31	-0.28	-0.48	-0.01
Total Current Assets	0.9	0.87	-0.8	-0.01	-0.12	0.01		-0.54	-0.01	-0.21	0.39	-0.07	0.21	-0.01	-0.48	0.01	0.9	0.42	-0.45	0.08	0.06	-0.09	-0.12	0.2
Intangible Assets	-0.59	-0.38	0.1	-0.33	0.07	-0.35	-0.54		-0.09	-0.18	0.01	-0.11	-0.24	-0.47	0.84	-0.44	-0.42	-0.09	0.14	-0.51	0.33	0.0	0.17	0.16
Accounts Payable	0.01	0.25	-0.02	-0.34	0.92	-0.36	-0.01	-0.09		0.33	0.29	-0.32	-0.09	-0.11	0.02	0.08	-0.1	-0.49	0.18	0.12	0.03	0.58	0.43	-0.71
Short Term Debt	0.1	-0.2	0.49	-0.27	0.15	0.53	-0.21	-0.18	0.33		0.18	-0.14	0.4	0.27	0.08	0.55	-0.28	-0.12	0.65	0.5	-0.34	-0.11	-0.35	-0.15
Common Stock	0.47	0.58	-0.37	-0.9	0.28	-0.2	0.39	0.01	0.29	0.18		-0.62	0.54	-0.29	0.16	0.3	0.55	0.59	-0.34	0.27	-0.18	-0.39	-0.41	0.27
Good Will	0.0	-0.09	0.12	0.49	-0.31	0.05	-0.07	-0.11	-0.32	-0.14	-0.62		-0.36	0.18	-0.24	-0.12	-0.31	-0.32	0.06	-0.11	-0.21	0.07	0.02	0.16
Property Plant Equipment	0.47	0.24	0.2	-0.41	-0.21	0.39	0.21	-0.24	-0.09	0.4	0.54	-0.36		0.56	-0.03	0.63	0.36	0.49	-0.31	0.6	-0.61	-0.52	-0.63	0.33
Short Term Investments	0.14	-0.14	0.49	0.38	-0.21	0.49	-0.01	-0.47	-0.11	0.27	-0.29	0.18	0.56		-0.31	0.33	-0.06	-0.1	-0.12	0.34	-0.53	-0.03	-0.14	-0.06
Current Deferred Revenue	-0.44	-0.4	0.24	-0.39	0.15	-0.03	-0.48	0.84	0.02	0.08	0.16	-0.24	-0.03	-0.31		-0.18	-0.45	-0.13	0.3	-0.25	0.19	0.02	0.07	-0.01
Long Term Debt	0.37	0.09	0.41	-0.22	-0.12	0.49	0.01	-0.44	0.08	0.55	0.3	-0.12	0.63	0.33	-0.18		0.04	0.07	0.04	0.99	-0.71	-0.3	-0.6	-0.09
Net Tangible Assets	0.79	0.84	-0.78	-0.2	-0.16	-0.12	0.9	-0.42	-0.1	-0.28	0.55	-0.31	0.36	-0.06	-0.45	0.04		0.69	-0.62	0.1	0.02	-0.32	-0.26	0.39
Capital Surpluse	0.41	0.37	-0.39	-0.42	-0.42	0.01	0.42	-0.09	-0.49	-0.12	0.59	-0.32	0.49	-0.1	-0.13	0.07	0.69		-0.49	0.04	-0.12	-0.79	-0.63	0.82
Short Long Term Debt	-0.35	-0.58	0.4	0.16	0.12	0.43	-0.45	0.14	0.18	0.65	-0.34	0.06	-0.31	-0.12	0.3	0.04	-0.62	-0.49		0.0	0.29	0.31	0.16	-0.38
Long Term Debt Total	0.42	0.16	0.35	-0.16	-0.08	0.45	0.08	-0.51	0.12	0.5	0.27	-0.11	0.6	0.34	-0.25	0.99	0.1	0.04	0.0		-0.7	-0.25	-0.55	-0.13
Cash And Equivalents	-0.3	-0.1	-0.5	0.19	0.17	-0.31	0.06	0.33	0.03	-0.34	-0.18	-0.21	-0.61	-0.53	0.19	-0.71	0.02	-0.12	0.29	-0.7		0.52	0.69	-0.15
Net Invested Capital	-0.28	-0.08	-0.07	0.35	0.6	-0.28	-0.09	0.0	0.58	-0.11	-0.39	0.07	-0.52	-0.03	0.02	-0.3	-0.32	-0.79	0.31	-0.25	0.52		0.92	-0.78
Net Working Capital	-0.44	-0.12	-0.19	0.35	0.55	-0.48	-0.12	0.17	0.43	-0.35	-0.41	0.02	-0.63	-0.14	0.07	-0.6	-0.26	-0.63	0.16	-0.55	0.69	0.92		-0.6
Capital Stock	0.24	0.18	-0.25	-0.28	-0.61	-0.01	0.2	0.16	-0.71	-0.15	0.27	0.16	0.33	-0.06	-0.01	-0.09	0.39	0.82	-0.38	-0.13	-0.15	-0.78	-0.6

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict Enzo Biochem

Return On Equity Over Time

Enzo Total Stockholder Equity

Total Stockholder Equity

74.79 Million

At this time, Enzo Biochem's Total Stockholder Equity is fairly stable compared to the past year.

Based on the latest financial disclosure, Enzo Biochem has a Return On Equity of -0.1459. This is 99.39% lower than that of the Health Care Providers & Services sector and 97.82% lower than that of the Health Care industry. The return on equity for all United States stocks is 52.94% lower than that of the firm.

Enzo Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enzo Biochem's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enzo Biochem could also be used in its relative valuation, which is a method of valuing Enzo Biochem by comparing valuation metrics of similar companies.

Enzo Biochem is currently under evaluation in return on equity category among its peers.

Enzo Fundamentals

	Return On Equity	-0.15
	Return On Asset	-0.0744
	Profit Margin	(0.82) %
	Operating Margin	(0.39) %
	Current Valuation	4.95 M
	Shares Outstanding	52.24 M
	Shares Owned By Insiders	23.72 %
	Shares Owned By Institutions	32.04 %
	Number Of Shares Shorted	432.99 K
	Price To Earning	26.60 X
	Price To Book	0.96 X
	Price To Sales	1.69 X
	Revenue	31.91 M
	Gross Profit	11.57 M
	EBITDA	(8.35 M)
	Net Income	(26.08 M)
	Cash And Equivalents	82.37 M
	Cash Per Share	0.44 X
	Total Debt	3.51 M
	Debt To Equity	0.38 %
	Current Ratio	2.21 X
	Book Value Per Share	1.07 X
	Cash Flow From Operations	(26.26 M)
	Short Ratio	3.94 X
	Earnings Per Share	(0.19) X
	Target Price	5.5
	Number Of Employees	125
	Beta	0.73
	Market Capitalization	53.81 M
	Total Asset	85.76 M
	Retained Earnings	(294.43 M)
	Working Capital	45.24 M
	Current Asset	91.4 M
	Current Liabilities	20.57 M
	Annual Yield	0.39 %
	Net Asset	85.76 M

About Enzo Biochem Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Enzo Biochem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enzo Biochem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enzo Biochem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Enzo Stock Analysis

When running Enzo Biochem's price analysis, check to measure Enzo Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzo Biochem is operating at the current time. Most of Enzo Biochem's value examination focuses on studying past and present price action to predict the probability of Enzo Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzo Biochem's price. Additionally, you may evaluate how the addition of Enzo Biochem to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC